PARP1 and small cell lung carcinoma: KEYLYNK-013 (NCT04624204), contrary to the previously mentioned trials in patients with relapsed SCLC, seeks to investigate the role of combinatory PARP inhibition (PARPi) with ICIs in the consolidative setting for LS-SCLC [41].